Demant A/S/€DEMANT

1D1W1MYTD1Y5YMAX

About Demant A/S

Demant A/S is a company specializing in hearing healthcare solutions. It operates in the medical technology industry, providing hearing aids, audiometric equipment, and hearing implants. The company also offers personal communication solutions and hearing care services through its retail network. Founded in 1904 and headquartered in Smørum, Denmark, Demant has a significant presence in Europe, North America, and other regions, serving users worldwide. The company's strategic positioning is strengthened by its focus on R&D and innovation, which supports its diverse product portfolio and ability to meet various customer needs in the hearing health market.
Ticker
€DEMANT
Sector
Health
Primary listing
XGAT
Employees
26,616
Headquarters
Smørum, Denmark
Website
www.demant.com

Demant A/S Metrics

BasicAdvanced
€8.4B
39.17
€1.02
0.76
-

Bulls say / Bears say

Demant delivered 7% organic growth in the first half of 2026, with momentum accelerating in the second quarter across hearing aids, hearing care and diagnostics. It raised its full-year organic growth target to 6–7% and EBIT before special items to DKK 4.4–4.8 billion. (Demant, MarketScreener)
Oticon Zeal is helping Demant grow faster than the hearing-aid market, with hearing-aid revenue up 9% organically in the first half and 10% in the second quarter. The new premium Oticon Reveal, featuring Dual AI sound processing, creates a further product-cycle catalyst and is being rolled out across major markets. (Demant, Oticon)
Profitability is improving alongside growth: gross margin reached 77.1%, up 1.1 percentage points year on year, while the cost programme delivered DKK 100 million of savings in the first half. Demant now expects the programme to add about DKK 300 million to 2026 EBIT before special items. (Demant, MarketScreener)
The strong first half has raised the bar for the second half, while several competitors are expected to launch products. Deutsche Bank therefore sees limited scope for a further re-rating and keeps a Hold view, despite raising its target price. (MarketScreener, Demant)
The improvement in reported earnings is not yet free of transition costs: Demant expects DKK 400 million of special items in 2026, including KIND integration expenses and severance and implementation costs from restructuring. The company is prioritising debt reduction over share buy-backs this year, which limits near-term shareholder distributions. (Demant, Quartr)
Demant still assumes only 3–4% value growth for the global hearing-aid market because of macroeconomic uncertainty, and expects currency movements to reduce 2026 EBIT before special items by about DKK 125 million. Its outlook also continues to flag uncertainty around global trade and tariffs. (Demant, Morningstar)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.